Literature DB >> 29871848

Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.

Ka Yang1, Yanling Song2, Haibo Xie1, Hao Wu1, Yi-Ting Wu3, Eric D Leisten1, Weiping Tang4.   

Abstract

Histone deacetylases (HDACs) decrease the acetylation level of histones and other non-histone proteins. Over expression of HDACs have been observed in cancers and other diseases. Targeted protein degradation by "hijacking" the natural ubiquitin-proteasome-system (UPS) recently emerged as a novel technology to "knock-out" endogenous disease-causing proteins. We applied this strategy to the development of the first small molecule degraders for zinc-dependent HDACs by conjugating non-selective HDAC inhibitors with E3 ubiquitin ligase ligands. Through cell-based assays, we discovered novel bifunctional molecules (dHDAC6) that could selectively degrade HDAC6. Further mechanistic studies indicated that HDAC6 was selectively removed by the UPS.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cereblon; Degrader; Epigenetic; HDAC; PROTAC; Thalidomide

Mesh:

Substances:

Year:  2018        PMID: 29871848     DOI: 10.1016/j.bmcl.2018.05.057

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  48 in total

1.  Selective degradation of CDK6 by a palbociclib based PROTAC.

Authors:  Sandeep Rana; Mourad Bendjennat; Smit Kour; Hannah M King; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2019-03-26       Impact factor: 2.823

Review 2.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 3.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 4.  Emerging modes-of-action in drug discovery.

Authors:  Eric Valeur; Frank Narjes; Christian Ottmann; Alleyn T Plowright
Journal:  Medchemcomm       Date:  2019-06-25       Impact factor: 3.597

5.  Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.

Authors:  Philip P Chamberlain; Laura A D'Agostino; J Michael Ellis; Joshua D Hansen; Mary E Matyskiela; Joseph J McDonald; Jennifer R Riggs; Lawrence G Hamann
Journal:  ACS Med Chem Lett       Date:  2019-11-12       Impact factor: 4.345

Review 6.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

7.  Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Authors:  Ka Yang; Hao Wu; Zhongrui Zhang; Eric D Leisten; Xueqing Nie; Binkai Liu; Zhi Wen; Jing Zhang; Michael D Cunningham; Weiping Tang
Journal:  ACS Med Chem Lett       Date:  2020-03-18       Impact factor: 4.345

8.  A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

Authors:  Ka Yang; Yu Zhao; Xueqing Nie; Hao Wu; Bo Wang; Chelsi M Almodovar-Rivera; Haibo Xie; Weiping Tang
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

9.  Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.

Authors:  Yufeng Xiao; Jia Wang; Lisa Y Zhao; Xinyi Chen; Guangrong Zheng; Xuan Zhang; Daiqing Liao
Journal:  Chem Commun (Camb)       Date:  2020-08-25       Impact factor: 6.222

Review 10.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.